Search Results - "Lotan, T. L."

Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia by Lotan, TL, Lyon, M, Huo, D, Taxy, JB, Brendler, C, Foster, BA, Stadler, W, Rinker-Schaeffer, CW

“…Identification of the signalling cascades that are differentially activated during prostatic tumourigenesis is a crucial step in the search for future…”
Get full text

In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading by Picanço-Albuquerque, C. G., Morais, C. L., Carvalho, F. L. F., Peskoe, S. B., Hicks, J. L., Ludkovski, O., Vidotto, T., Fedor, H., Humphreys, E., Han, M., Platz, E. A., De Marzo, A. M., Berman, D. M., Lotan, T. L., Squire, J. A.

“…The prognostic value of phosphatase and tensin homolog (PTEN) loss in prostate cancer has primarily been evaluated by either fluorescence in situ hybridization…”
Get full text

Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion by Gumuskaya, B, Gurel, B, Fedor, H, Tan, H-L, Weier, C A, Hicks, J L, Haffner, M C, Lotan, T L, De Marzo, A M

“…Background: ERG rearrangements and PTEN (phosphatase and tensin homolog deleted on chromosome 10) loss are two of the most common genetic alterations in…”
Get full text

Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics by Sutera, P., Van der Eecken, K., Kishan, A.U., Hamid, A., Grist, E., Attard, G., Lotan, T.L., Mendes, A., Sweeney, C., Paller, C., Carducci, M., Ross, A.E., Pienta, K., Feng, F.Y., Eisenberger, M., Antonarakis, E.S., Ost, P., Tran, P.T., Deek, M.P.

“…Recent evidence has suggested metastatic cancer represents a disease spectrum rather than a binary state and metastasis-directed therapy (MDT) such as…”
Get full text

845PDCDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors by Antonarakis, E S, Velho, P Isaacsson, Agarwal, N, Santos, V Sacristan, Maughan, B L, Pili, R, Adra, N, Sternberg, C N, Vlachostergios, P J, Tagawa, S T, Bryce, A H, McNatty, A L, Reichert, Z R, Dreicer, R, Sartor, O, Lotan, T L, Hussain, M

“…Abstract Background Although once considered a homologous recombination DNA repair gene, CDK12 is now thought to have a distinct role in maintaining genomic…”
Get full text

Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer by Lotan, Tamara L., Tomlins, Scott A., Bismar, Tarek A., Van der Kwast, Theodorus H., Grignon, David, Egevad, Lars, Kristiansen, Glen, Pritchard, Colin C., Rubin, Mark A., Bubendorf, Lukas

“…The combined clinical and molecular heterogeneity of prostate cancer necessitates the use of prognostic, predictive, and diagnostic biomarkers to assist the…”
Get full text

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer by Ahearn, Thomas U, Pettersson, Andreas, Ebot, Ericka M, Gerke, Travis, Graff, Rebecca E, Morais, Carlos L, Hicks, Jessica L, Wilson, Kathryn M, Rider, Jennifer R, Sesso, Howard D, Fiorentino, Michelangelo, Flavin, Richard, Finn, Stephen, Giovannucci, Edward L, Loda, Massimo, Stampfer, Meir J, De Marzo, Angelo M, Mucci, Lorelei A, Lotan, Tamara L

“…PTEN is a tumor suppressor frequently deleted in prostate cancer that may be a useful prognostic biomarker. However, the association of PTEN loss with lethal…”
Get full text

Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions by Stopsack, Konrad H, Su, Xiaofeng A, Vaselkiv, J Bailey, Graff, Rebecca E, Ebot, Ericka M, Pettersson, Andreas, Lis, Rosina T, Fiorentino, Michelangelo, Loda, Massimo, Penney, Kathryn L, Lotan, Tamara L, Mucci, Lorelei A

“…The most common somatic event in primary prostate cancer is a fusion between the androgen-related TMPRSS2 gene and the ERG oncogene. Tumors with these fusions,…”
Get full text